Lilie L. Lin

Associate Professor

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Purpose Inhibitors of poly(ADP-ribose) polymerase (PARP), an enzyme with numerous roles in DNA damage response signaling, represent a class of anti-cancer drugs approved for treating solid tumors with defects in the DNA damage response. However, additional methods for identifying patients who would benefit from the use of PARP inhibitors are urgently needed. We evaluated a novel radiotracer, 18 F-FluorThanatrace ([ 18 F]-FTT), to noninvasively assess PARP activity with PET/CT before treatment and determine associations between uptake, tumor mutation status, and prior receipt of therapy including PARP inhibitors. Methods Fifty-two patients with solid tumors underwent whole-body (skull base to thigh) [ 18 F]-FTT PET/CT scans before beginning PARP inhibitor treatment. The maximum standardized uptake value (SUVmax) was recorded for up to five lesions per patient. All recorded lesions were included in the analysis. Results Uptake of [ 18 F]-FTT was confirmed in all 52 patients regardless of primary tumor type (20 breast, 12 ovarian, 7 prostate, 3 pancreas, and 10 other). Lesion-by-lesion analysis revealed significant differences in [ 18 F]-FTT uptake by primary tumor type ( P < 0.001) and higher uptake in lesions with BRCA2 mutations ( n = 65) than in lesions with other genetic mutations ( n = 26) (6.7 vs. 5.5, P = 0.03). Prior receipt of PARP inhibitor was associated with lower SUVmax (4.7 vs. 6.4, P = 0.001), and prior receipt of systemic therapy was also associated with lower SUVmax (4.0 vs. 6.0, P = 0.01). Conclusions [ 18 F]-FTT PET/CT may be useful as a noninvasive quantitative assessment of PARP1 enzyme activity in patients with solid tumors; uptake of [ 18 F]-FTT varies based on tumor mutational status and receipt of prior PARP inhihbitor therapy and/or systemic therapy.

Year:

2025

1. ABSTRACT Purpose Radiotherapy treatment planning is a resource-intensive process characterized by multiple manual steps and clinical hand-offs that contribute to treatment delays and inter-observer variability. The Radiation Planning Assistant (RPA) is a web-based platform designed to deliver automated contouring and planning approaches tailored to low-resource settings. This work expands the RPA to develop and clinically validate end-to-end, AI-driven workflows for prostate and cervical cancers, designed to improve efficiency, consistency, and accessibility in low- and middle-income countries (LMICs). Methods We developed deep learning-based auto-contouring models using nnU-Net and integrated them with knowledge-based planning (KBP) models trained on curated datasets from over 1,000 prostate and 110 cervical cancer treatment plans. For prostate cancer, models were developed to accommodate prostate directed, prostate bed, and nodal treatment scenarios. Cervical cancer planning followed EMBRACE II guidelines and included pelvic and para-aortic nodal volumes. These tools were integrated into the RPA. Clinical acceptability of the auto-contours and plans was assessed retrospectively by radiation oncologists using a five-point Likert scale. Results In total, 50 test patients (40 prostate, 10 cervical) were evaluated. For prostate cancer, 70% of target auto-contours and 73% of treatment plans were clinically acceptable without edits; for cervical cancer, these rates were 80% and 80%, respectively. For prostate cancer planning, 77% of target and 98% of organ-at-risk structures met all per-protocol compliance criteria. For cervical cancer planning, all EMBRACE II protocol hard constraint criteria were met. Bowel and vaginal contours demonstrated lower performance, but these did not compromise plan quality. Conclusion We present validated, end-to-end radiotherapy planning workflows for prostate and cervical cancers that leverage the RPA’s infrastructure to streamline treatment planning in a globally accessible platform and demonstrate high clinical acceptability. By reducing reliance on specialist input, this work addresses key barriers to equitable radiotherapy access in resource-limited settings and responds to global calls from the IAEA and WHO to expand radiotherapy capacity. Funding National Institute of Health, National Science Foundation, Rising Tide Foundation, University of Texas MD Anderson Cancer Center

Year:

2025

Purpose: Human papillomavirus (HPV) is a significant cause of cervical cancer. We hypothesized that detecting viral cell-free HPV DNA (cfDNA) before, during, and after chemoradiation (chemoRT) could provide insights into disease extent, clinical staging, and treatment response. Experimental Design: A total of 66 patients with locally advanced cervical cancer were enrolled between 2017 and 2023, with 49 receiving standard-of-care treatment and 17 participating in a clinical trial combining a therapeutic HPV vaccine (PDS0101; IMMUNOCERV). Plasma was collected at baseline, weeks 1, 3, and 5 of chemoRT, and 3 to 4 months after chemoRT. HPV cfDNA was quantified using droplet digital PCR targeting the HPV E6/E7 oncogenes of 13 high-risk types. MRI was performed at baseline and before brachytherapy. Results: The median follow-up was 23 months, with recurrence-free survival (RFS) of 78.4% at 2 years. Baseline nodal disease extent correlated with HPV cfDNA levels. HPV cfDNA levels peaked in week 1 of radiation and decreased through treatment. Patients receiving the PDS0101 vaccine had a higher rate of undetectable HPV type 16 cfDNA compared with those who received standard-of-care therapy. HPV cfDNA clearance correlated with better 2-year RFS (92.9% vs. 30%, log-rank; P = 0.0067). The strongest predictor of RFS was HPV cfDNA clearance in follow-up achieving a concordance index score of 0.83, which improved when combined with MRI response (concordance index, 0.88). Conclusions: HPV cfDNA levels change dynamically during chemoRT. HPV cfDNA levels at follow-up predict RFS, and delivery of therapeutic HPV vaccine with chemoRT was linked to rapid HPV cfDNA decline. Monitoring HPV cfDNA during and after chemoRT may guide tailoring of personalized treatment.

Year:

2025

Purpose: PARP inhibitors have become the standard-of-care treatment for homologous recombination deficient (HRD) high-grade serous ovarian cancer (HGSOC). However, not all HRD tumors respond to PARPi. Biomarkers to predict response are needed. [ 18 F]FluorThanatrace ([ 18 F]FTT) is a PARPi-analog PET radiotracer that noninvasively measures PARP-1 expression. Herein, we evaluate [ 18 F]FTT as a biomarker to predict response to PARPi in patient-derived xenograft (PDX) models and subjects with HRD HGSOC. Experimental Design: In PDX models, [ 18 F]FTT-PET was performed before and after PARPi (olaparib), ataxia-telangiectasia inhibitor (ATRi), or both (PARPi-ATRi). Changes in [ 18 F]FTT were correlated with tumor volume changes. Subjects were imaged with [ 18 F]FTT-PET at baseline and after ∼1 week of PARPi. Changes in [ 18 F]FTT-PET uptake were compared with changes in tumor size (RECISTv1.1), CA-125, and progression-free survival (PFS). Results: A decrease in [ 18 F]FTT tumor uptake after PARPi correlated with response to PARPi, or PARPi-ATRi treatment in PARPi-resistant PDX models ( r = 0.77–0.81). In subjects ( n = 11), percent difference in [ 18 F]FTT-PET after ∼7 days of PARPi compared with baseline correlated with best RECIST response ( P = 0.01), best CA-125 response ( P = 0.033), and PFS ( P = 0.027). All subjects with >50% reduction in [ 18 F]FTT uptake had >6-month PFS and >50% reduction in CA-125. Utilizing only baseline [ 18 F]FTT uptake did not predict such responses. Conclusions: The decline in [ 18 F]FTT uptake shortly after PARPi initiation provides a measure of drug-target engagement and shows promise as a biomarker to guide PARPi therapies in this pilot study. These results support additional preclinical mechanistic and clinical studies in subjects receiving PARPi ± combination therapy. See related commentary by Liu and Zamarin, p. 1384

Year:

2025

Background: With extended lifespans for people with human immunodeficiency virus (PWH), there is a corresponding increased burden of chronic illnesses, including cancer. Our objective was to estimate the excess mortality among PWH with cancer compared with people without HIV (PWoH), accounting for the higher background mortality in the general PWH population. Methods: We identified 39,000 PWH and 387,767 demographically matched PWoH in three integrated healthcare systems from 2000 to 2016. We estimated excess mortality among PWH with cancer, computed as the cancer mortality rate difference-in-difference comparing PWH and PWoH. We evaluated five cancer groups: any cancer; virus-, human papillomavirus–, and Epstein–Barr virus –related cancers; virus-unrelated cancers, and common individual cancers. We fitted a multivariable additive Poisson model to estimate excess mortality among PWH with cancer. Results: PWH with any cancer had excess mortality compared with PWoH [41.3/1,000 person-years (py), 95% confidence interval (CI), 34.0–48.7]. The highest excess mortality was observed for Epstein–Barr virus–related cancers (63.2/1,000 py, 95% CI, 47.8–78.7), lung cancer (147.7/1,000 py, 95% CI, 41.1–254.3), and non–Hodgkin lymphoma (70.5/1,000 py, 95% CI, 51.4–89.6). Excess mortality among PWH was attenuated from 2009 to 2016, and PWH with cancer had no excess mortality 5 years after diagnosis. Conclusion: PWH in care may have excess mortality from certain cancer types, although disparities may have attenuated over time and do not persist beyond 5 years after diagnosis. Impact: Findings may guide improved clinical practice and suggest further research is needed to investigate whether cancer treatment or other factors contribute to mortality disparities for PWH with cancer.

Year:

2024

Purpose The human papillomavirus (HPV) is a significant cause of cervical cancer. We hypothesized that detecting viral cell-free HPV DNA (cfDNA) before, during, and after chemoradiation (chemoRT) could provide insights into disease extent, clinical staging, and treatment response. Experimental Design Sixty-six patients with locally advanced cervical cancer were enrolled between 2017 and 2023, with 49 receiving standard-of-care (SOC) treatment and 17 participating in a clinical trial combining a therapeutic HPV vaccine (PDS0101; IMMUNOCERV). Plasma samples were collected at baseline, during weeks 1, 3, and 5 of chemoRT, and 3-4 months after chemoRT. HPV cfDNA was quantified using droplet digital PCR targeting the HPV E6/E7 oncogenes of 13 high-risk types. MRI was performed at baseline and before brachytherapy. Results The median follow-up was 23 months, with recurrence-free survival (RFS) of 78.4% at 2 years. Baseline nodal disease extent correlated with HPV cfDNA levels. HPV cfDNA levels peaked in week 1 of radiation and decreased through treatment. Patients receiving the PDS0101 vaccine had a higher rate of undetectable HPV type 16 cfDNA compared to SOC. HPV cfDNA clearance correlated with better 2-yr RFS (92.9% vs. 30%, log-rank p=0.0067). The strongest predictor of RFS was HPV cfDNA clearance in follow-up achieving a concordance index (CI) 0.83, which improved when combined with MRI response (CI 0.88). Conclusions HPV cfDNA levels change dynamically during chemoRT. HPV cfDNA levels at first follow-up predict RFS, and the therapeutic HPV vaccine was linked to rapid HPV cfDNA decline. Monitoring HPV cfDNA during and after chemoRT may guide tailoring of personalized treatment.

Year:

2024

PURPOSE The incidence of cancer in sub-Saharan Africa is increasing rapidly, yet cancer research in the region continues to lag. One contributing factor is limited exposure to clinical research among trainees. We describe implementation and results of a virtual clinical research training program for Zambian clinical oncology fellows developed jointly by the Cancer Diseases Hospital in Zambia and the MD Anderson Cancer Center to address this need. METHODS The clinical research training program consisted of 14 weekly virtual lectures, development of research questions by Zambian clinical oncology fellows, assignment of faculty and peer mentors, longitudinal mentorship of research protocols, and anonymous precourse and postcourse surveys. The paired t-test was used to analyze the change in academic self-efficacy scores. RESULTS Fourteen Zambian clinical oncology fellows participated. Senior fellows were paired with research mentors, leading to the development of eight research protocols. A total of 70 meetings and 126 hours of mentorship occurred with a median of seven meetings and 15 hours per pairing. The precourse and postcourse survey response rates were 86% and 79%, respectively. There were statistically significant increases in nine of 12 academic self-efficacy domains. The largest gains were in ability to independently perform research ( P < .001) and research mentorship ( P = .02) with an average increase of 1.5 points on a five-point scale in both domains. CONCLUSION The Cancer Diseases Hospital MD Anderson Cancer Center clinical research training program for Zambian clinical oncology fellows led to increases in multiple academic self-efficacy domains among participants, formation of longitudinal mentorship groups with both faculty and peer mentors, and development of Zambian-led research protocols, demonstrating the feasibility of implementing a virtual model. This may be especially relevant because of shifting international collaboration paradigms after the COVID-19 pandemic.

Year:

2022

Collaborators (24)

Aradhana Venkatesan

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Gordon Mills

Professor

Oregon Health & Science University

UNITED STATES
View details

David Swanson

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Steven Frank

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jennifer Kramer

Baylor College of Medicine

UNITED STATES
View details

Kamaria Lee

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Elizabeth Chiao

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Lainie Martin

University of Pennsylvania Perelman School of Medicine

UNITED STATES
View details

Laurence Court

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Robert Mach

Britton Chance Professor

University of Pennsylvania

UNITED STATES
View details

Fiona Simpkins

-

UNITED STATES
View details

David A. Mankoff

Matthew J Wilson Professor and Research Vice-Chair of Radiology

University of Pennsylvania

UNITED STATES
View details

Lauren Colbert

Professor

Duke University

UNITED STATES
View details

Janos Tanyi

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Megan Jacobsen

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Carlos Cardenas

Associate Professor

The University of Alabama

UNITED STATES
View details

Kyoko Yoshida-Court

Senior Research Scientist

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Beth M. Beadle

Professor

Stanford University

UNITED STATES
View details

Maura L. Gillison

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Drew Torigian

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Tucker Netherton

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Henriette Burger

Head of Division

Stellenbosch University

SOUTH AFRICA
View details

Sarah Gitto

Assistant Research Professor

University of Pennsylvania

UNITED STATES
View details

Peng Wei

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details